Auron Therapeutics, Inc.

We’re excited to welcome @SergeMesserlian to the @Auron Board! We are confident that Serge’s insights and leadership will be invaluable as we continue to grow and innovate. We look forward to achieving great things together, Serge!   #Welcome #BoardofDirectors #CancerResearch 

I am pleased to join Kate Yen and the Board of Directors at Auron Therapeutics, Inc. The Company pioneered its AURIGIN™ platform, which uses AI and machine learning to compare normal cell states with cancerous cell states, to identify novel cancer targets, optimal development models, and biomarkers to facilitate proper patient selection. Using AURIGIN, Auron is building a pipeline of small molecule targeted therapies, led by AUTX-703, which is being developed for the treatment of both solid tumors, including small cell lung cancer and neuroendocrine prostate cancer, and hematologic malignancies, including acute myeloid leukemia. We have significant opportunity ahead to make an impact on the lives of patients!

Excited to present an overview of our AURIGIN platform at the AI in Biomedicine Keystone Symposia on May 3rd! We use AURIGIN to identify, prioritize, and validate key driver of cancer cell states, and then apply deep structure-based drug design to develop novel, targeted small molecule therapies. Join us as we combat the complex and evolving nature of cancer! #AURIGIN #AI #CancerResearch #KeystoneSymposia

We’re excited to be at the American Association for Cancer Research's annual meeting, highlighting our platform and sharing our progress in developing next-generation targeted therapies for patients. Look for our presentations and reach out to connect with us!   #AACR #AACR24 #AACR2024 #CancerResearch

Meet AURIGIN, our revolutionary platform for drug discovery. This proprietary technology is designed to identify and facilitate the development of novel targets that can treat the most challenging aspects of cancer biology. AURIGIN is our beacon in the quest for new, effective cancer treatments, leading us towards a better future for patients. Stay tuned as we redefine the boundaries of possibility!   #drugdiscovery #InnovateToCure #cancerresearch

What is cell state plasticity – and why is it a critical pathway for cancer?   In normal, healthy development, cells divide rapidly and proliferate to form the body’s tissues and organs. Once cells evolve to their final cell type, they lose the ability to proliferate. Cancer hijacks this process, keeping cells in the plastic state to use that high proliferation ability to grow tumors.   At Auron, we’re identifying and targeting the drivers of those altered cellular states, reverting cancer cells from a proliferative plastic state to a normal, dormant state to stop the growth of the tumor.   Read more about cell state plasticity here: https://bit.ly/4bLFlcd  #science #cancerresearch #biotech  

We’re excited to share Auron will have two poster presentations at this year’s American Association for Cancer Research's annual meeting. The abstracts present an overview of our proprietary AURIGIN™ platform and the first preclinical data from our lead program. We are exploring how this research can be used for conditions including small cell lung cancer, neuroendocrine prostate cancer and acute myeloid leukemia.   Read more in our press release - https://bit.ly/3V5hQok - and make sure to attend our presentation at #AACR2024 in San Diego.

What is cell state plasticity – and why is it a critical pathway for cancer?   In normal, healthy development, cells divide rapidly and proliferate to form the body’s tissues and organs. Once cells evolve to their final cell type, they lose the ability to proliferate. Cancer hijacks this process, keeping cells in the plastic state to use that high proliferation ability to grow tumors.   At Auron, we’re identifying and targeting the drivers of those altered cellular states, reverting cancer cells from a proliferative plastic state to a normal, dormant state to stop the growth of the tumor.   Read more about cell state plasticity here: https://bit.ly/4bLFlcd   #science #cancerresearch #biotech #biotechnology #oncology #oncologyresearch #cancer  

#ICYMI: We recently announced our first development candidate selection – read more about our progress in advancing a next-generation targeted cancer treatment for small cell lung cancer, neuroendocrine prostate cancer and acute myeloid leukemia: https://bit.ly/49wNyPp #CancerResearch #AACR2024 #AML #Leukemia #LungCancer #SCLC #ProstateCancer

Read about Auron’s latest news, the selection of our first development candidate, in BioWorld: https://bit.ly/49wNyPp   #CancerResearch #AACR2024 #AML #Leukemia #LungCancer #SCLC #ProstateCancer